Genentech, a member of the Roche Group (RHHBY), said Thursday that the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application or sBLA for Tecentriq (atezolizumab) in combination with Abraxane (albumin-bound paclitaxel; nab-paclitaxel) and carboplatin for the initial or first-line treatment of people with metastatic non-squamous non-small cell lung cancer or NSCLC, who do not have EGFR or ALK genomic tumor aberrations.
from RTT - Biotech http://bit.ly/2RRtyml
via IFTTT
No comments:
Post a Comment